SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.15), $0.05 worse than the analyst estimate of ($1.10).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- Goldman Sachs downgrades Zegna after luxury stock outpaces peers
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
